Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $429.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective hoisted by Canaccord Genuity Group from $415.00 to $429.00 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

ALNY has been the subject of several other reports. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Needham & Company LLC dropped their target price on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Royal Bank Of Canada decreased their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a report on Tuesday, January 20th. Wells Fargo & Company lowered their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 20th. Finally, Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $477.96.

Alnylam Pharmaceuticals Trading Up 2.0%

Alnylam Pharmaceuticals stock opened at $339.37 on Tuesday. Alnylam Pharmaceuticals has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The firm has a market capitalization of $45.01 billion, a price-to-earnings ratio of 198.46 and a beta of 0.35. The company has a 50 day moving average price of $368.11 and a 200 day moving average price of $423.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.61). The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. Alnylam Pharmaceuticals’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.65) earnings per share. Research analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the firm’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70. Following the transaction, the executive vice president owned 21,264 shares in the company, valued at approximately $7,874,697.12. This trade represents a 9.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Pushkal Garg sold 2,242 shares of the company’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the sale, the executive vice president owned 24,848 shares of the company’s stock, valued at $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 36,578 shares of company stock worth $12,416,105 over the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $27,000. HM Payson & Co. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $27,000. Golden State Wealth Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $429 and kept a buy rating, signaling meaningful upside versus the current quote. Canaccord price-target raise
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $510 price target (~50% above the current level), providing a bullish benchmark for upside expectations. HC Wainwright note
• Positive Sentiment: Freedom Capital upgraded ALNY from Hold to Strong-Buy, adding to positive analyst momentum. Freedom Capital upgrade
• Positive Sentiment: Large institutional buying reported in Q4 (notable stake increases by Guggenheim, Caisse, Schonfeld and AQR) suggests strong institutional conviction and supports liquidity/demand for the shares.
• Neutral Sentiment: Short-interest entries in the feed show zero/NaN and a 0.0 days-to-cover figure — this looks like a data/reporting artifact rather than new shorting pressure; treat as non-actionable until exchange-confirmed data appears.
• Neutral Sentiment: Analysts collectively trimmed some near-term targets but still express confidence in 2026 growth — mixed model adjustments rather than a broad sell-off. Analysts trim targets
• Negative Sentiment: Several insiders sold shares this week, including CEO Yvonne Greenstreet (~6,958 shares) and multiple senior executives (Kevin Fitzgerald, Pushkal Garg, others). Large, clustered insider sales can weigh on sentiment even if they are routine or pre-planned. CEO sale SEC filing
• Negative Sentiment: Chardan trimmed its price target to $425 (a modest downgrade relative to some peers), and ALNY’s most recent quarterly report showed an EPS miss (Feb. 12) despite strong revenue growth — reminders of execution/near-term margin risk. Chardan target cut

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.